Treating the right patient at the right time: Access to heart failure care

Canadian Journal of Cardiology

Volumn 22, Issue 9, 2006, Pages 749-754

  Ross, Heather ^a,k   Howlett, J ^b   Arnold, J Malcolm O ^c   Liu, P ^a   O'Neill, B J ^b   Brophy, J M ^d   Simpson, C S ^e   Sholdice, M M ^f   Knudtson, M ^g   Ross, D B ^h   Rottger, J ⁱ   Glasgow, K ^j  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f Canadian Cardiovascular Society   (Canada)

^g LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ Cardiac Care Network of Ontario ^*

^j Cardiac Care Network of Ontario   (Canada)

^k TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

Access; Heart failure; Waiting times

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

CANADA; CONSENSUS DEVELOPMENT; CONSULTATION; EVIDENCE BASED MEDICINE; FAX; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTERNET; MEDICAL ASSESSMENT; MEDICAL EXPERT; MEDICAL INFORMATION; MEDICAL SPECIALIST; MORTALITY; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TELEHEALTH; TELEPHONE; TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 33747187262     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70290-2     Document Type: Article

References (31)

1. Naylor CD, Slaughter PM, eds. Cardiovascular Health and Services in Ontario: An ICES Atlas. Toronto: Institute for Clinical Evaluative Sciences, 1999:16-49.
2. Johansen H, Strauss B, Arnold JM, Moe G, Liu P. On the rise: The current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol 2003;19:430-5.
3. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402.
4. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602.
5. Rodriguez-Artalejo F, Guallar-Castillon P, Banegas Banegas JR, del Rey Calero, J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J 1997;18:1771-9.
6. Jaagosild P, Dawson NV, Thomas C, et al. Outcomes of acute exacerbation of severe congestive heart failure: Quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. Arch Intern Med 1998;158:1081-9.
7. Lee DS, Mamdani MM, Austin PC, et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 2004;116:581-9.
8. Atienza F, Anguita M, Martinez-Alzamora N, et al; PRICE Study Group. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. Eur J Heart Fail 2004;6:643-52.
9. Gustafsson F, Arnold JM. Heart failure clinics and outpatient management: Review of the evidence and call for quality assurance. Eur Heart J 2004;25:1596-604.
10. DeBusk RF, Miller NH, Parker KM, et al. Care management for low-risk patients with heart failure: A randomized, controlled trial. Ann Intern Med 2004;141:606-13.
11. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
12. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-32.
13. Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community,based population with heart failure. Circulation 2004;110:3518-26.
14. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: A systematic review of randomized trials. J Am Coll Cardiol 2004;44:810-9.
15. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: A meta-analysis. JAMA 2004;291:1358-67. (Erratum in 2004;292:1022).
16. Roccaforte R, Demers C, Baldassarre F, Teo KK, Yusuf S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 2005;7:1133-44.
17. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: A randomised controlled study. Lancet 1999;354:1077-83.
18. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998:80;437-41.
19. Ducharme A, Doyon O, White M, Rouleau JL, Brophy JM. Impact of care at a multidisciplinary congestive heart failure clinic: A randomized trial. CMAJ 2005;173:40-5.
20. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302.
21. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
22. Pfeffer MA, Swedberg K, Granger CB, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362:759-66.
23. Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
24. Bristow MR, Saxon LA, Boehmer J, et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
25. Cleland JG, Daubert JC, Erdmann E, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
26. Arnold JM, Liu P, Demers C, et al; Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Can J Cardiol 2006;22:23-45. (Erratum 2006;22:271).
27. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82. (Erratum in 2006;47:1503-05).
28. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
29. White HD, Aylward PE, Huang Z, et al; VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: Results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005;112:3391-9.
30. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
31. Lee DS, Tran C, Flintoft V, Grant FC, Liu PP, Tu JV; Canadian Cardiovascular Outcomes Research Team/Canadian Cardiovascular Society Heart Failure Quality Indicator Panel. CCORT/CCS quality indicators for congestive heart failure care. Can J Cardiol 2003;19:357-64.